Coherus Targets Amgen's Enbrel Patent In IPR
Coherus BioSciences Inc. on Friday asked the U.S. Patent Trial and Appeal Board to review the patentability of an Amgen patent covering a method for making etanercept, the active ingredient in...To view the full article, register now.
Already a subscriber? Click here to view full article